Amgen

Company

Investment-firm

Last deal

$28.5B

Amount

Post-IPO Debt

Stage

12.12.2022

Date

1

all rounds

$28.5B

Total amount

General

About Company
Amgen develops innovative therapeutics to improve patients' lives.

Industry

Sector :

Subsector :

founded date

01.01.1980

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Debt

IPO status

Private

Description

Amgen is a leading biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics. They use advanced human genetics to understand diseases and improve health outcomes. With a strong track record since 1980, Amgen has reached millions of patients worldwide and is known for its expertise in renal disease and cancer supportive-care products. They have a diverse portfolio of flagship drugs, including red blood cell boosters, immune system boosters, and treatments for inflammatory diseases. Amgen has also expanded into the field of oncology through acquisitions and has recently launched drugs for cholesterol-lowering, migraine, lung cancer, and asthma. Additionally, they have a biosimilar portfolio that includes alternatives to well-known drugs such as Avastin, Herceptin, and Humira.
Contacts

Phone number

Social url